| Gene symbol | ERBB2 | Synonyms | CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2, p185(erbB2) | Type of gene | protein-coding | |
| Chromosome | 17 | Map location | 17q12 | dbXrefs | Entrez:2064 MIM:164870 HGNC:HGNC:3430 Ensembl:ENSG00000141736 AllianceGenome:HGNC:3430 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | erb-b2 receptor tyrosine kinase 2 | |||||
| GTO ID | GTC2746 |
| Trial ID | NCT04995003 |
| Disease | Dedifferentiated Liposarcoma | Childhood Soft Tissue Sarcoma | Osteosarcoma | Synovial Sarcoma | Ewing Sarcoma | Rhabdomyosarcoma |
| Altered gene | HER2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | HER2 CAR-T cells |
| Co-treatment | pembrolizumab |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma |
| Year | 2021 |
| Country | United States |
| Company sponsor | Baylor College of Medicine |
| Other ID(s) | H-49271 HEROS 3.0|R01CA276684 |
| Cohort 1 | |||||||||||||
|
|||||||||||||